Mark Allen

About

Mark Allen is a pioneering figure in lipidomics and glycoscreening, whose work has fundamentally advanced the molecular understanding of cardiovascular disease. His research centers on the development and application of high-resolution mass spectrometry platforms for complex biomolecular analysis. Allen’s major contribution lies in his systematic lipid profiling of human atherosclerotic plaques, a landmark study (210 citations) that employed chip-based robotic nanoelectrospray to reveal the detailed lipid composition of arterial lesions, providing critical insights into plaque biology and potential therapeutic targets. He is also recognized for coupling automated chip electrospray ionization with Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, enabling high-performance glycoscreening and carbohydrate sequencing (44 citations). This technical innovation, alongside his work on ganglioside analysis using high-capacity ion traps (70 citations), established robust, automated workflows for structural biology. By bridging engineering and clinical biochemistry, Allen has equipped researchers with powerful tools to dissect lipid and glycan complexity, leaving a lasting impact on both analytical chemistry and translational medicine.

Research Focus

Key Achievements

Top Papers

1. 1
   Comparative Lipidomics Profiling of Human Atherosclerotic Plaques

   210 citations · 2011
2. 2
   Coupling of fully automated chip-based electrospray ionization to high-capacity ion trap mass spectrometer for ganglioside analysis

   70 citations · 2008
3. 3
   Coupling of fully automated chip electrospray to Fourier transform ion cyclotron resonance mass spectrometry for high‐performance glycoscreening and sequencing

   44 citations · 2004

Key Collaborators

Contact & Links